{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:48:11Z","timestamp":1788522491006,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["NIGMS T32 GM068412, NCATS TL1 TR002735"],"award-info":[{"award-number":["NIGMS T32 GM068412, NCATS TL1 TR002735"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA214046"],"award-info":[{"award-number":["R01 CA214046"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rare, recurrent balanced translocations occur in a variety of cancers but are often not functionally interrogated. Balanced translocations with the immunoglobulin heavy chain locus (<jats:italic>IGH<\/jats:italic>; 14q32) in chronic lymphocytic leukemia (CLL) are infrequent but have led to the discovery of pathogenic genes including <jats:italic>CCND1<\/jats:italic>, <jats:italic>BCL2<\/jats:italic>, and <jats:italic>BCL3<\/jats:italic>. Following identification of a t(X;14)(q28;q32) translocation that placed the mature T cell proliferation 1 gene (<jats:italic>MTCP1<\/jats:italic>) adjacent to the immunoglobulin locus in a CLL patient, we hypothesized that this gene may have previously unrecognized importance. Indeed, here we report overexpression of human <jats:italic>MTCP1<\/jats:italic> restricted to the B cell compartment in mice produces a clonal CD5<jats:sup>+<\/jats:sup>\/CD19<jats:sup>+<\/jats:sup> leukemia recapitulating the major characteristics of human CLL and demonstrates favorable response to therapeutic intervention with ibrutinib. We reinforce the importance of genetic interrogation of rare, recurrent balanced translocations to identify cancer driving genes via the story of <jats:italic>MTCP1<\/jats:italic> as a contributor to CLL pathogenesis.<\/jats:p>","DOI":"10.1038\/s41467-021-26400-x","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T14:10:44Z","timestamp":1636121444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-1527","authenticated-orcid":false,"given":"Janek S.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Hing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan N.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey B.","family":"Cempre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry P.","family":"Beaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga M.","family":"Labanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Mr\u00f3zek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9612-6473","authenticated-orcid":false,"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Gulcin","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6163-1779","authenticated-orcid":false,"given":"Vincenzo","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1965-4920","authenticated-orcid":false,"given":"Pearlly","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9830-0711","authenticated-orcid":false,"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-9400","authenticated-orcid":false,"given":"Rosa","family":"Lapalombella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"26400_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek, M., Shanafelt, T. D. & Eichhorst, B. Chronic lymphocytic leukaemia. Lancet 391, 1524\u20131537 (2018).","journal-title":"Lancet"},{"key":"26400_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ccr.2011.06.029","volume":"20","author":"Y Kikushige","year":"2011","unstructured":"Kikushige, Y. et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246\u2013259 (2011).","journal-title":"Cancer Cell"},{"key":"26400_CR3","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1182\/blood-2008-09-176149","volume":"113","author":"TD Shanafelt","year":"2009","unstructured":"Shanafelt, T. D. et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 113, 4188\u20134196 (2009).","journal-title":"Blood"},{"key":"26400_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.3488","volume":"48","author":"CC Oakes","year":"2016","unstructured":"Oakes, C. C. et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat. Genet. 48, 253\u2013264 (2016).","journal-title":"Nat. Genet."},{"key":"26400_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41591-018-0028-4","volume":"24","author":"R Beekman","year":"2018","unstructured":"Beekman, R. et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat. Med. 24, 868\u2013880 (2018).","journal-title":"Nat. Med."},{"key":"26400_CR6","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner, H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910\u20131916 (2000).","journal-title":"N. Engl. J. Med."},{"key":"26400_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525\u2013530 (2015).","journal-title":"Nature"},{"key":"26400_CR8","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1002\/ijc.33235","volume":"147","author":"C P\u00e9rez-Carretero","year":"2020","unstructured":"P\u00e9rez-Carretero, C. et al. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. Int. J. Cancer 147, 2780\u20132792 (2020).","journal-title":"Int. J. Cancer"},{"key":"26400_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood.V96.3.808","volume":"96","author":"TG Willis","year":"2000","unstructured":"Willis, T. G. & Dyer, M. J. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96, 808\u2013822 (2000).","journal-title":"Blood"},{"key":"26400_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1084\/jem.171.2.559","volume":"171","author":"M Adachi","year":"1990","unstructured":"Adachi, M., Tefferi, A., Greipp, P. R., Kipps, T. J. & Tsujimoto, Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J. Exp. Med. 171, 559\u2013564 (1990).","journal-title":"J. Exp. Med."},{"key":"26400_CR11","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada, S. et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 91, 3379\u20133389 (1998).","journal-title":"Blood"},{"key":"26400_CR12","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA 102, 13944\u201313949 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","volume":"17","author":"U Klein","year":"2010","unstructured":"Klein, U. et al. The DLEU2\/miR-15a\/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28\u201340 (2010).","journal-title":"Cancer Cell"},{"key":"26400_CR14","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin, G. A. et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524\u201315529 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"26400_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/sj.onc.1201303","volume":"15","author":"C Gritti","year":"1997","unstructured":"Gritti, C. et al. Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations. Oncogene 15, 1329\u20131335 (1997).","journal-title":"Oncogene"},{"key":"26400_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1008279616063","volume":"11","author":"YS Yang","year":"1998","unstructured":"Yang, Y. S. et al. Solution structure of the recombinant human oncoprotein p13MTCP1. J. Biomol. NMR 11, 337\u2013354 (1998).","journal-title":"J. Biomol. NMR"},{"key":"26400_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0969-2126(98)00017-3","volume":"6","author":"F Hoh","year":"1998","unstructured":"Hoh, F. et al. Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel \u03b2-barrel topology. Structure 6, 147\u2013155 (1998).","journal-title":"Structure"},{"key":"26400_CR19","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1073\/pnas.95.7.3413","volume":"95","author":"ZQ Fu","year":"1998","unstructured":"Fu, Z. Q. et al. Crystal structure of MTCP-1: implications for role of TCL-1 and MTCP-1 in T cell malignancies. Proc. Natl Acad. Sci. USA 95, 3413\u20133418 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR20","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1100\/tsw.2002.826","volume":"2","author":"JM Petock","year":"2002","unstructured":"Petock, J. M. et al. Crystal structures of Tcl1 family oncoproteins and their conserved surface features. ScientificWorldJournal\u00a02, 1876\u20131884 (2002).","journal-title":"ScientificWorldJournal"},{"key":"26400_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/jmbi.2001.4928","volume":"312","author":"C Roumestand","year":"2001","unstructured":"Roumestand, C., Boyer, M., Guignard, L., Barthe, P. & Royer, C. A. Characterization of the folding and unfolding reactions of a small beta-barrel protein of novel topology, the MTCP1 oncogene product P13. J. Mol. Biol. 312, 247\u2013259 (2001).","journal-title":"J. Mol. Biol."},{"key":"26400_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1128\/MCB.22.5.1513-1525.2002","volume":"22","author":"G K\u00fcnstle","year":"2002","unstructured":"K\u00fcnstle, G. et al. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol. Cell Biol. 22, 1513\u20131525 (2002).","journal-title":"Mol. Cell Biol."},{"key":"26400_CR23","first-page":"2475","volume":"8","author":"MH Stern","year":"1993","unstructured":"Stern, M. H. et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha\/delta locus in mature T cell proliferations. Oncogene 8, 2475\u20132483 (1993).","journal-title":"Oncogene"},{"key":"26400_CR24","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood.V87.5.1923.1923","volume":"87","author":"A Madani","year":"1996","unstructured":"Madani, A. et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood 87, 1923\u20131927 (1996).","journal-title":"Blood"},{"key":"26400_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood.V92.2.368","volume":"92","author":"C Gritti","year":"1998","unstructured":"Gritti, C. et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 92, 368\u2013373 (1998).","journal-title":"Blood"},{"key":"26400_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/sj.leu.2404476","volume":"21","author":"M Joiner","year":"2007","unstructured":"Joiner, M., Le Toriellec, E., Despouy, G. & Stern, M. H. The MTCP1 oncogene modifies T-cell homeostasis before leukemogenesis in transgenic mice. Leukemia 21, 362\u2013366 (2007).","journal-title":"Leukemia"},{"key":"26400_CR27","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","volume":"29","author":"JA Woyach","year":"2011","unstructured":"Woyach, J. A. et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J. Clin. Oncol. 29, 1349\u20131355 (2011).","journal-title":"J. Clin. Oncol."},{"key":"26400_CR28","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","volume":"28","author":"TS Lin","year":"2010","unstructured":"Lin, T. S. et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J. Clin. Oncol. 28, 4500\u20134506 (2010).","journal-title":"J. Clin. Oncol."},{"key":"26400_CR29","doi-asserted-by":"publisher","first-page":"19643","DOI":"10.1073\/pnas.0810965105","volume":"105","author":"Y Pekarsky","year":"2008","unstructured":"Pekarsky, Y. et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc. Natl Acad. Sci. USA 105, 19643\u201319648 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR30","first-page":"e62","volume":"45","author":"C Cain-Hom","year":"2017","unstructured":"Cain-Hom, C. et al. Efficient mapping of transgene integration sites and local structural changes in Cre transgenic mice using targeted locus amplification. Nucleic Acids Res. 45, e62 (2017).","journal-title":"Nucleic Acids Res."},{"key":"26400_CR31","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi, R. et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl Acad. Sci. USA 99, 6955\u20136960 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR32","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","volume":"108","author":"AJ Johnson","year":"2006","unstructured":"Johnson, A. J. et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 108, 1334\u20131338 (2006).","journal-title":"Blood"},{"key":"26400_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.leu.2403588","volume":"19","author":"A Kosmaczewska","year":"2005","unstructured":"Kosmaczewska, A., Ciszak, L., Suwalska, K., Wolowiec, D. & Frydecka, I. CTLA-4 overexpression in CD19+\/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia 19, 301\u2013304 (2005).","journal-title":"Leukemia"},{"key":"26400_CR34","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.4049\/jimmunol.1801359","volume":"202","author":"P Do","year":"2019","unstructured":"Do, P. et al. Leukemic B cell CTLA-4 suppresses costimulation of T cells. J. Immunol. 202, 2806\u20132816 (2019).","journal-title":"J. Immunol."},{"key":"26400_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/0300985810363705","volume":"47","author":"X Hao","year":"2010","unstructured":"Hao, X. et al. The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyte-associated lymphoma of mice. Vet. Pathol. 47, 434\u2013445 (2010).","journal-title":"Vet. Pathol."},{"key":"26400_CR36","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1073\/pnas.1503587112","volume":"112","author":"JS Blachly","year":"2015","unstructured":"Blachly, J. S. et al. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 112, 4322\u20134327 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.leu.2404457","volume":"21","author":"P Ghia","year":"2007","unstructured":"Ghia, P. et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 21, 1\u20133 (2007).","journal-title":"Leukemia"},{"key":"26400_CR38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 123, 1207\u20131213 (2014).","journal-title":"Blood"},{"key":"26400_CR39","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1172\/JCI114320","volume":"84","author":"JT Lee","year":"1989","unstructured":"Lee, J. T., Innes, D. J. & Williams, M. E. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin\u2019s lymphoma. J. Clin. Invest. 84, 1454\u20131459 (1989).","journal-title":"J. Clin. Invest."},{"key":"26400_CR40","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares, P., Colomer, D. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. J. Clin. Invest. 122, 3416\u20133423 (2012).","journal-title":"J. Clin. Invest."},{"key":"26400_CR41","doi-asserted-by":"publisher","first-page":"11590","DOI":"10.1158\/0008-5472.CAN-06-3613","volume":"66","author":"Y Pekarsky","year":"2006","unstructured":"Pekarsky, Y. et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66, 11590\u201311593 (2006).","journal-title":"Cancer Res."},{"key":"26400_CR42","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.leukres.2007.05.020","volume":"31","author":"RL Browning","year":"2007","unstructured":"Browning, R. L. et al. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk. Res. 31, 1737\u20131740 (2007).","journal-title":"Leuk. Res."},{"key":"26400_CR43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/sj.leu.2404017","volume":"20","author":"M Herling","year":"2006","unstructured":"Herling, M. et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20, 280\u2013285 (2006).","journal-title":"Leukemia"},{"key":"26400_CR44","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1182\/blood-2009-03-208256","volume":"114","author":"M Herling","year":"2009","unstructured":"Herling, M. et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 114, 4675\u20134686 (2009).","journal-title":"Blood"},{"key":"26400_CR45","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1073\/pnas.1500010112","volume":"112","author":"V Balatti","year":"2015","unstructured":"Balatti, V. et al. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 112, 2169\u20132174 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR46","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2008-06-160713","volume":"113","author":"C Holler","year":"2009","unstructured":"Holler, C. et al. PKC\u03b2 is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC\u03b2 as a therapeutic target in chronic lymphocytic leukemia. Blood 113, 2791\u20132794 (2009).","journal-title":"Blood"},{"key":"26400_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/gcc.22840","volume":"59","author":"SX Li","year":"2020","unstructured":"Li, S. X. et al. Identification of a t(X;17)(q28;q21) generating a KANSL1-MTCP1 gene fusion leading to dysregulated expression of MTCP1 in acute myeloid leukemia. Genes Chromosomes Cancer 59, 417\u2013421 (2020).","journal-title":"Genes Chromosomes Cancer"},{"key":"26400_CR48","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ejmg.2012.03.001","volume":"55","author":"DI Jonsson","year":"2012","unstructured":"Jonsson, D. I. et al. A de novo 1.13 Mb microdeletion in 12q13.13 associated with congenital distal arthrogryposis, intellectual disability and mild dysmorphism. Eur. J. Med. Genet. 55, 437\u2013440 (2012).","journal-title":"Eur. J. Med. Genet."},{"key":"26400_CR49","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1002\/ajmg.a.34324","volume":"155A","author":"N Okamoto","year":"2011","unstructured":"Okamoto, N., Tamura, D., Nishimura, G., Shimojima, K. & Yamamoto, T. Submicroscopic deletion of 12q13 including HOXC gene cluster with skeletal anomalies and global developmental delay. Am. J. Med. Genet. A 155A, 2997\u20133001 (2011).","journal-title":"Am. J. Med. Genet. A"},{"key":"26400_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejmg.2012.12.003","volume":"56","author":"M Hancarova","year":"2013","unstructured":"Hancarova, M. et al. Chromosome 12q13.13 deletions involving the HOXC gene cluster: phenotype and candidate genes. Eur. J. Med. Genet. 56, 171\u2013173 (2013).","journal-title":"Eur. J. Med. Genet."},{"key":"26400_CR51","doi-asserted-by":"publisher","first-page":"E943","DOI":"10.1073\/pnas.1100132108","volume":"108","author":"N Dompe","year":"2011","unstructured":"Dompe, N. et al. A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proc. Natl Acad. Sci. USA 108, E943\u201351 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26400_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ng.510","volume":"42","author":"D Crowther-Swanepoel","year":"2010","unstructured":"Crowther-Swanepoel, D. et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132\u2013136 (2010).","journal-title":"Nat. Genet."},{"key":"26400_CR53","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/leu.2008.102","volume":"22","author":"E Chapiro","year":"2008","unstructured":"Chapiro, E. et al. The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia. Leukemia 22, 2123\u20132127 (2008).","journal-title":"Leukemia"},{"key":"26400_CR54","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1309\/AJCPOEFP3SLX6HXJ","volume":"135","author":"YO Huh","year":"2011","unstructured":"Huh, Y. O. et al. Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. Am. J. Clin. Pathol. 135, 686\u2013696 (2011).","journal-title":"Am. J. Clin. Pathol."},{"key":"26400_CR55","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123, 1810\u20131817 (2014).","journal-title":"Blood"},{"key":"26400_CR56","first-page":"2259","volume":"10","author":"A Madani","year":"1995","unstructured":"Madani, A. et al. The 8 kD product of the putative oncogene MTCP-1 is a mitochondrial protein. Oncogene 10, 2259\u20132262 (1995).","journal-title":"Oncogene"},{"key":"26400_CR57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/leu.2017.177","volume":"32","author":"A Burns","year":"2018","unstructured":"Burns, A. et al. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups. Leukemia 32, 332\u2013342 (2018).","journal-title":"Leukemia"},{"key":"26400_CR58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cels.2016.10.021","volume":"3","author":"JM Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez, J. M. et al. The BLUEPRINT Data Analysis Portal. Cell Syst. 3, 491\u2013495.e495 (2016).","journal-title":"Cell Syst."},{"key":"26400_CR59","unstructured":"Becton, Dickinson & company. B-Cell Research. Flow cytometry tools for the study of B-cell biology. (2014)."},{"key":"26400_CR60","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","volume":"131","author":"K Pieper","year":"2013","unstructured":"Pieper, K., Grimbacher, B. & Eibel, H. B-cell biology and development. J. Allergy Clin. Immunol. 131, 959\u2013971 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"26400_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.coi.2008.03.014","volume":"20","author":"D Allman","year":"2008","unstructured":"Allman, D. & Pillai, S. Peripheral B cell subsets. Curr. Opin. Immunol. 20, 149\u2013157 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"26400_CR62","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-19-0273","volume":"25","author":"F Lucas","year":"2019","unstructured":"Lucas, F. et al. E\u03bc-TCL1xMyc: a novel mouse model for concurrent CLL and B-cell lymphoma. Clin. Cancer Res. 25, 6260\u20136273 (2019).","journal-title":"Clin. Cancer Res."},{"key":"26400_CR63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"26400_CR64","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015).","journal-title":"F1000Res"},{"key":"26400_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"26400_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02247-6","volume":"18","author":"LA Walker","year":"2020","unstructured":"Walker, L. A. et al. CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq. J. Transl. Med. 18, 63 (2020).","journal-title":"J. Transl. Med."},{"key":"26400_CR67","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"26400_CR68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0962280206074463","volume":"16","author":"S van Buuren","year":"2007","unstructured":"van Buuren, S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat. Methods Med. Res. 16, 219\u2013242 (2007).","journal-title":"Stat. Methods Med. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26400-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T03:08:30Z","timestamp":1675825710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26400-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26400"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26400-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"25 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.B. has performed consulting for AbbVie, AstraZeneca, Innate, and KITE Pharma. J.C.B. performed consulting for AstraZeneca, Takada, Novartis, Pharmacyclics, Syndex, and Trillium. J.C.B. chairs the scientific board of Vincera Pharmaceuticals and has significant equity in this company. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6338"}}